Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
LINC01839 (long intergenic non-protein coding RNA 1839) is an autonomously transcribed non-coding RNA more than 200 nucleotides in length, which does not overlap annotated protein-coding genes[3][4][5]. It is a member of the lincRNA class, which is known to play roles in gene and chromatin regulation, RNA stabilization, and sometimes enhancer activity, through cis and trans mechanisms[5][7]. LINC01839, also previously known as EIF2B5-IT1, is located at chromosome 3q27.1[4]. While the lincRNA family is increasingly recognized in disease biology, such as cancer, the specific functional and clinical roles of LINC01839 remain to be fully elucidated[3][4][5].\n\nThere is no evidence that LINC01839 is a druggable receptor or enzyme, and it is not a classic therapeutic target. Current research does not indicate approved drugs interacting with it or its use as a biomarker or with notable safety concerns[3][4][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on long intergenic non-protein coding RNA 1839 (LINC01839).